Rocket Pharmaceuticals is trading 5.1% down at $3.46 as high-risk growth names face selling pressure amid broader market and biotech sector weakness.
- No fresh company-specific news or regulatory filings were identified for the July 16 session to explain the move.
- Investor sentiment remains cautious following prior clinical trial setbacks and an ongoing securities lawsuit related to the company's Danon disease program.